Bristol Myers Squibb Beats Q1 Revenue and EPS Estimates, Reaffirms Strong Outlook
Summary
Bristol Myers Squibb reported strong first-quarter results, with adjusted earnings per share of $1.58 and revenue of $11.49 billion, both surpassing analyst expectations of $1.42 and $10.93 billion, respectively. This positive performance is largely attributed to a 12% increase in sales from its growth portfolio, which offset a 6% decline in its legacy portfolio due to generic competition. The company also reaffirmed its full-year guidance, noting that revenue and earnings are trending towards the upper end of its previously shared ranges. This robust financial update, demonstrating resilience and growth despite challenges, is a significant positive catalyst for the stock. Traders will be watching for continued momentum in the growth portfolio and the company's strategy to mitigate legacy product declines.
At the time of this announcement, BMY was trading at $57.88 on NYSE in the Life Sciences sector, with a market capitalization of approximately $117.6B. The 52-week trading range was $42.52 to $62.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.